| Bio Roundup: Sage Postpartum Help, Biogen Bids Adu, Heart Beats & More | Alex Lash | 03/22/19 | National |
| Quentis Nets $48M For Cancer Drugs, Building Buzz For NY Bio Startups | Ben Fidler | 02/27/18 | New York |
| In Biggest Biotech IPO of 2017, Denali Raises $248M for Neuro Drugs | Frank Vinluan | 12/08/17 | San Francisco |
| Bio Roundup: RNAi’s Big Day, CAR-T For Kids, Drugs From Fungi & More | Ben Fidler | 09/22/17 | National |
| HubSpot Buys Dating App, Joule Winds Down, & More Boston Tech News | Jeff Bauter Engel | 09/07/17 | Boston |
| Stalled or Rising Momentum? New York Wrestles With Its Biotech Future | Ben Fidler | 05/10/17 | New York |
| Seventh Sense Gets Initial FDA Clearance for Simple Blood-Draw Device | Jeff Bauter Engel | 02/23/17 | Boston |
| Varmus, Sato on Steering De Blasio’s $500M Plan to Grow NY Biotech | Ben Fidler | 12/30/16 | New York |
| Bio Roundup: NY Rises, Prez Inks Cures, Ophthotech Crashes & More | Alex Lash | 12/16/16 | National |
| Flagship Pioneers New Name, $285M ‘Special Opportunities’ Fund | Frank Vinluan | 12/15/16 | Boston |
| NY Bio Surge Continues as De Blasio Unveils $500M, 10-Year Life Sci Plan | Ben Fidler | 12/13/16 | New York |
| Seventh Sense Biosystems Sucks In $10M for Simple Blood-Draw Device | Jeff Bauter Engel | 11/18/16 | Boston |
| New York Institutions, VCs Team up to Build Drug Discovery “Bridge” | Ben Fidler | 10/31/16 | New York |
| New Rockefeller Prez Takes Stock of “Wildly Underdeveloped” NY Bio Scene | Ben Fidler | 09/27/16 | New York |
| Eleven Bio Buys Viventia, Rebrands as Cancer Drug Developer | Ben Fidler | 09/21/16 | Boston |
| Seeking to Join Editas, Intellia, CRISPR Tx Makes Long Awaited IPO Push | Ben Fidler | 09/12/16 | Boston |
| Filing: Moderna Blowing Past Record $450M Round With New $600M Raise | Ben Fidler | 08/29/16 | Boston |
| 3D Printing Startup NVBots Nabs Cash & New CEO, Moves Into Metal | Jeff Bauter Engel | 08/18/16 | Boston |
| In a Microbiome Setback, Seres Drug Fails in Phase 2, Shares Crushed | Ben Fidler | 07/29/16 | Boston |
| With $40M Bid, Pfizer Set to Buy, And Close, Bankrupt Bind Tx | Ben Fidler | 07/27/16 | Boston |
| Indigo’s Microbial Tech for Crops Lands $100M to Fight Plant Stresses | Frank Vinluan | 07/21/16 | Boston |
| With Bugs As Drugs, Evelo CEO Plans Immune, Cancer Trials in 2017 | Alex Lash | 07/12/16 | Boston |
| Pfizer Might Buy Bind Therapeutics From Bankruptcy for $20M | David Holley | 07/06/16 | Boston |
| Syros Cuts Price But Bags $50M in IPO to Fuel Cancer Drug Trials | Ben Fidler | 06/29/16 | Boston |
| Alexandria Sets up Incubator, $25M Seed Fund For NY Bio Startups | Ben Fidler | 06/08/16 | New York |
| Pronutria Rebrands as Axcella Health, Forms “Nutrition” Subsidiary | Ben Fidler | 06/07/16 | Boston |
| Syros Files For IPO to Push “Gene Control” Drugs Through First Trials | Ben Fidler | 06/06/16 | Boston |
| Retooled Selecta Bio Takes Crossover Cash to IPO Queue | Ben Fidler | 05/24/16 | Boston |
| CarGurus CEO on Profitable Tech Startups, and Why Uber Is Road Kill | Jeff Bauter Engel | 05/16/16 | Boston |
| Amid Leadership Changes, NY Biotech Braces For its “Pivotal Moment” | Ben Fidler | 05/12/16 | New York |
